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BoBACKGROUND Contemporary reconsideration of diagnostic N-terminal pro–B-type natriuretic peptide (NT-proBNP)
cutoffs for diagnosis of heart failure (HF) is needed.
OBJECTIVES This study sought to evaluate the diagnostic performance of NT-proBNP for acute HF in patients with
dyspnea in the emergency department (ED) setting.
METHODS Dyspneic patients presenting to 19 EDs in North America were enrolled and had blood drawn for subsequent
NT-proBNP measurement. Primary endpoints were positive predictive values of age-stratiﬁed cutoffs (450, 900, and
1,800 pg/ml) for diagnosis of acute HF and negative predictive value of the rule-out cutoff to exclude acute HF. Sec-
ondary endpoints included sensitivity, speciﬁcity, and positive (þ) and negative () likelihood ratios (LRs) for acute HF.
RESULTS Of 1,461 subjects, 277 (19%) were adjudicated as having acute HF. The area under the receiver-operating
characteristic curve for diagnosis of acute HF was 0.91 (95% conﬁdence interval [CI]: 0.90 to 0.93; p < 0.001).
Sensitivity for age stratiﬁed cutoffs of 450, 900, and 1,800 pg/ml was 85.7%, 79.3%, and 75.9%, respectively;
speciﬁcity was 93.9%, 84.0%, and 75.0%, respectively. Positive predictive values were 53.6%, 58.4%, and 62.0%,
respectively. Overall LRþ across age-dependent cutoffs was 5.99 (95% CI: 5.05 to 6.93); individual LRþ for
age-dependent cutoffs was 14.08, 4.95, and 3.03, respectively. The sensitivity and negative predictive value for the
rule-out cutoff of 300 pg/ml were 93.9% and 98.0%, respectively; LR was 0.09 (95% CI: 0.05 to 0.13).
CONCLUSIONS In acutely dyspneic patients seen in the ED setting, age-stratiﬁed NT-proBNP cutpoints may aid in the
diagnosis of acute HF. An NT-proBNP <300 pg/ml strongly excludes the presence of acute HF. (J Am Coll Cardiol
2018;71:1191–200) © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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1192N atriuretic peptide testing (B-typenatriuretic peptide [BNP] and itsamino-terminal pro-peptide cleav-
age equivalent, N-terminal pro–B-type natri-
uretic peptide [NT-proBNP]) aids in the
diagnosis of acute heart failure (HF) (1–4).
These biomarkers are now embedded as
Class I, Level of Evidence: A in clinical prac-
tice guidelines (5). Understanding the
optimal means to interpret natriuretic pep-
tide tests has evolved, and recent changes
in certain characteristics of patients affected
by HF suggest the need to reassess the cur-
rent natriuretic peptide diagnostic cutoffs.
Such changes include shifting HF demo-
graphics (6,7), including more prevalent
renal disease and atrial ﬁbrillation, which
possibly contributes to higher biomarker
concentrations (8). Conversely, increasingincidence and prevalence of HF with preserved ejec-
tion fraction and patient obesity, both of which may
result in lower natriuretic peptide concentrations,
may require lower BNP or NT-proBNP cutoffs. Simi-
larly, the growing use of HF medications inﬂuencing
BNP or NT-proBNP values (such as neprilysin inhibi-
tion) may also change optimal cutoffs for diagnosis
of acute exacerbation of HF.SEE PAGE 1201Data from the PRIDE (N-Terminal Pro-BNP Inves-
tigation of Dyspnea in the Emergency Department)
and ICON (International Collaborative of NT-proBNP)
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received November 2, 2017; revised manuscript received Januar900, and 1,800 pg/ml for age categories of <50, 50 to
75, and >75 years, respectively, for the identiﬁcation
of acute HF (9), along with an age-independent cutoff
of 300 pg/ml to exclude acute HF. These cutoffs have
been widely endorsed (1,5,10); however, they differ
substantially from the Food and Drug Administration
(FDA)–approved cutoffs for NT-proBNP (125 and 450
pg/ml for <75 and $75 years of age) (11), which are
optimized for outpatient exclusion of ambulatory HF.
Thus, there is a need to reconsider which cutoffs
should be used, as continued reliance on current,
approved cutoffs has the potential for diagnostic in-
accuracy, particularly for test speciﬁcity.
In light of these current gaps, the aim of the ICON-
RELOADED (ICON: Re-evaluation of Acute Diagnostic
Cut-Offs in the Emergency Department) study is to
validate the age-speciﬁc NT-proBNP cutoffs identiﬁed
in the ﬁrst ICON study in a contemporary cohort. We
hypothesized that the original ICON strategy for
NT-proBNP interpretation would remain useful
for diagnostic evaluation of HF in an all-comer
population of patients with dyspnea.
METHODS
STUDY DESIGN. The rationale and design of the
ICON-RELOADED study has been previously
described (12). The study was a prospective, multi-
center clinical trial conducted at 19 sites in the United
States and Canada. Brieﬂy, subjects 22 years of age or
older presenting to emergency departments (EDs)
with complaints of dyspnea (deﬁned as a subjective
feeling of shortness of breath, difﬁcult or laboredman Coulter, Spingotech, Ortho Clinical Diagnostics,
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FIGURE 1 CONSORT Diagram
74 (4%) Excluded Due to Clinical Criteria*†
223 (13%) Excluded Due to Sample Criteria
1461 Patients Enrolled
1424 (97%) from the United States
37 (3%) from Canada
ICON-RELOADED STUDY
1758 Patients Included
Patients were included in the study only if both clinical and sample criteria
were met. *Data are presented nonhierarchically; 2 subjects also had sample
exclusion criteria but are only counted in this box. †57 subjects included in
this box met the clinical criteria but did not have a baseline blood sample.
ICON-RELOADED ¼ ICON: Re-evaluation of Acute Diagnostic Cut-Offs in
the Emergency Department.
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1193breathing) were enrolled, and were blindly and
independently assessed for the presence of acute HF.
A blood sample was taken at enrollment.
A clinical events adjudication committee, blinded
to NT-proBNP results (obtained either by the hospital
or by the study), independently reviewed and adju-
dicated the diagnosis of acute HF. The institutional
review board at each participating institution
approved the study, and all patients provided writ-
ten, informed consent before enrollment. Patients
provided additional written, informed consent prior
to giving the biorepository blood sample.
STUDY OBJECTIVES. The primary objective of this
study was to externally validate the use of Elecsys
proBNP II (Roche Diagnostics, Indianapolis, Indiana)
concentrations to aid in the diagnosis or exclusion of
acute HF in patients presenting emergently through
use of the ICON cutpoint strategy (9).
STUDY ENDPOINTS. The primary efﬁcacy endpoints
for this study were the positive predictive value (PPV)
of age-speciﬁc rule-in cutoffs of 450, 900, and 1,800
pg/ml for ages <50, 50 to 75, and >75 years, respec-
tively, for the diagnosis of acute HF, and the negative
predictive value (NPV) of the rule-out cutoff of 300
pg/ml to exclude the adjudicated diagnosis of acute
HF. Secondary endpoints included the NPV, positive
likelihood ratio (LRþ), sensitivity, and speciﬁcity for
the age-speciﬁc rule-in cutoffs, as well as the negative
likelihood ratio (LR), sensitivity, and speciﬁcity for
the rule-out cutoff. Other secondary endpoints
included the PPV of all age-based rule-in cutoffs
combined for the adjudicated diagnosis of acute HF
by region (United States and Canada), and the NPV of
the rule-out cutoff by region.
NT-proBNP MEASUREMENTS. A cobase 601 analyzer
(Roche Diagnostics) was used for all NT-proBNP
measurements.
STATISTICAL ANALYSES. The study was designed to
include 1,765 patients to ensure a sample size of at
least 1,500 analyzable patients, assuming 15%
attrition.
Receiver-operating characteristic (ROC) curves for
performance of NT-proBNP for diagnosis of acute HF
were constructed. Operating characteristics for each
cutoff for rule-in and the proposed cutoff for rule-out
relative to the gold-standard diagnosis were evalu-
ated, including sensitivity, speciﬁcity, PPV, NPV,
LRþ, and LR. Estimates and 95% conﬁdence in-
tervals (CIs) were determined for the NPV and PPV
parameters (13), and separately for LRþ and LR
using a nonlinear mixed-effects model. The signiﬁ-
cance of an elevated age-adjusted NT-proBNP value
was further assessed by multivariable logisticregression analyses using backward elimination.
Variables entered into the model were pre-speciﬁed
as: history of diabetes mellitus, hypertension, or
prior HF; history including a chief complaint of
orthopnea; physical examination ﬁndings of pulmo-
nary rales or peripheral edema; and testing results
including estimated glomerular ﬁltration rate, chest
radiography revealing interstitial edema, as well as an
elevated age-adjusted NT-proBNP. Variables were
retained in the ﬁnal model with an alpha level of 0.2;
odds ratios (ORs) with 95% CIs were generated along
with estimation of an overall C-statistic for the model.
Based on data generated in the ICON study (9),
overall sensitivity and speciﬁcity of the proposed
age-dependent cutoffs were expected to be 90.0% and
84.0%, respectively. The expected prevalence of acute
HF was 50% with a PPV of 85.0%, and the LRþ was
expected to be 5.62. This expectation was based on the
prevalence observed in the original ICON study (9).
With 1,500 analyzable patients and an assumed HF
prevalence of 50% (9), the anticipated lower bounds
of a 95% 2-sided CI for the hypothesized PPV and
LRþ were 86.2% and 4.77, respectively (14). With
1,275 analyzable patients from the United States, the
lower bounds were anticipated to be 82.5% and 4.6
for PPV and LRþ, respectively.
The expected sensitivity and speciﬁcity values of
the rule-out cutoff of 300 pg/ml were 99.0% and
60.0%, respectively (9). Thus, the expected NPV was
98.5% (96.7% lower bound of the 95% CI) and the
expected LR was 0.017 (0.034 upper bound of the
TABLE 1 Baseline Characteristics of Enrolled Patients
All Patients
(N ¼ 1,461)
Patients With Acute HF
(n ¼ 277)
Patients Without Acute HF
(n ¼ 1,184) p Value
Age, yrs 56.4  15.7 63.9  13.4 54.6  15.6 <0.001
Female 49.1 (718/1,461) 39.0 (108/277) 51.5 (610/1,184) <0.001
Body mass index, kg/m2 (N ¼ 1,346) (n ¼ 267) (n ¼ 1,079) <0.001
32.0  9.2 33.8  9.9 31.5  9.0
Race 0.01
American Indian or Alaska Native 0.3 (4/1,432) 0.4 (1/271) 0.3 (3/1,161)
Asian 1.5 (21/1,432) 1.8 (5/271) 1.4 (16/1,161)
Black or African American 36.6 (524/1,432) 27.3 (74/271) 38.8 (450/1,161)
Native Hawaiian or other Paciﬁc Islander 0.6 (9/1,432) 0.7 (2/271) 0.6 (7/1,161)
White 59.6 (853/1,432) 69.0 (187/271) 57.4 (666/1,161)
Other 1.5 (21/1,432) 0.7 (2/271) 1.6 (19/1,161)
Hispanic or Latino 13.6 (191/1,406) 8.9 (24/270) 14.7 (167/1,136) 0.01
Medical history
Diabetes mellitus 28.9 (420/1,454) 45.3 (125/276) 25.0 (295/1,178) <0.001
Hypertension 63.3 (921/1,455) 86.2 (237/275) 58.0 (684/1,180) <0.001
Heart failure 24.9 (356/1,431) 68.2 (182/267) 14.9 (174/1,164) <0.001
Peripheral arterial disease 4.3 (61/1,434) 9.1 (24/265) 3.2 (37/1,169) <0.001
Implantable cardioverter-deﬁbrillator 5.9 (86/1,452) 15.6 (43/276) 3.7 (43/1,176) <0.001
Cardiac resynchronization therapy 1.7 (24/1,442) 4.4 (12/270) 1.0 (12/1,172) <0.001
Coronary artery bypass graft 6.6 (96/1,451) 15.4 (42/272) 4.6 (54/1,179) <0.001
Prior coronary artery disease 21.2 (307/1,445) 37.5 (103/275) 17.4 (204/1,170) <0.001
Prior myocardial infarction 13.2 (188/1,428) 24.3 (65/268) 10.6 (123/1,160) <0.001
Prior percutaneous coronary intervention 8.9 (128/1,431) 16.3 (44/270) 7.2 (84/1,161) <0.001
Renal insufﬁciency/failure 7.8 (114/1,455) 19.6 (54/275) 5.1 (60/1,180) <0.001
eGFR CKD-EPI, ml/min/1.73 m2 (N ¼ 1,323) (n ¼ 269) (n ¼ 1,054) <0.001
81.7  27.9 64.3  27.0 86.2  26.4
Most recent LVEF prior to enrollment (N ¼405) (n ¼ 143) (n ¼ 262) <0.001
51.0  17.1 41.7  18.2 56.1  14.2
LVEF <0.001
<50% 33.6 (136/405) 58.7 (84/143) 19.8 (52/262)
$50% 66.4 (269/405) 41.3 (59/143) 80.2 (210/262)
Atrial ﬁbrillation 14.9 (216/1,453) 34.3 (94/274) 10.3 (122/1,179) <0.001
Signiﬁcant mitral valve disease 4.2 (57/1,372) 11.6 (30/259) 2.4 (27/1,113) <0.001
Signiﬁcant aortic valve disease 2.3 (31/1,338) 6.1 (15/247) 1.5 (16/1,091) <0.001
Asthma 30.1 (437/1,450) 15.9 (44/276) 33.5 (393/1,174) <0.001
COPD 27.5 (399/1,449) 24.4 (67/275) 28.3 (332/1,174) 0.19
History/lung cancer 2.8 (40/1,454) 1.8 (5/276) 3.0 (35/1,178) 0.41
Alcohol history 0.30
Never 36.6 (514/1,404) 36.6 (94/257) 36.6 (420/1,147)
Former 16.4 (230/1,404) 19.5 (50/257) 15.7 (180/1,147)
Current 47.0 (660/1,404) 44.0 (113/257) 47.7 (547/1,147)
Tobacco history <0.001
Never 41.5 (591/1,423) 39.9 (107/268) 41.9 (484/1,155)
Former 36.7 (522/1,423) 45.9 (123/268) 34.5 (399/1,155)
Current 21.8 (310/1,423) 14.2 (38/268) 23.5 (272/1,155)
Cocaine history 0.03
Never 89.0 (1,227/1,379) 84.6 (214/253) 90.0 (1,013/1,126)
Former 10.4 (144/1,379) 14.6 (37/253) 9.5 (107/1,126)
Current 0.6 (8/1,379) 0.8 (2/253) 0.5 (6/1,126)
Values are mean  SD or % (n/N).
COPD ¼ chronic obstructive pulmonary disease; eGFR CKD-EPI ¼ estimated glomerular ﬁltration rate chronic kidney disease epidemiology collaboration equation; HF ¼ heart
failure; LVEF ¼ left ventricular ejection fraction.
Januzzi, Jr. et al. J A C C V O L . 7 1 , N O . 1 1 , 2 0 1 8
NT-proBNP in the Emergency Department M A R C H 2 0 , 2 0 1 8 : 1 1 9 1 – 2 0 0
1194
FIGURE 2 NT-proBNP Values Between Diagnostic Groups
Acute HF (N = 277)
Diagnostic Category Median NT-proBNP Inter-Quartile Range
Patients without Acute HF
Patients with Acute HF
98 pg/mL
2844 pg/mL
35-369 pg/mL
1247-5976 pg/mL
0
5000
15000
NT
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BN
P 
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g/
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20000
No Acute HF (N = 1184)
P < 0.001
Concentrations of NT-proBNP were considerably higher in those patients with acute HF
(p< 0.001). HF ¼ heart failure; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide.
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119595% CI) (14). Additionally, as described previously
(12), analyses were performed in pre-speciﬁed diag-
nostic subgroups. Baseline characteristics were
compared between subjects with and without acute
HF, using the Student’s t test for continuous vari-
ables, the Pearson chi-square test for categorical
variables, and the Fisher exact test for categorical
variables with small counts.
RESULTS
A total of 1,758 patients were enrolled from October
30, 2015, to October 15, 2016. Of these, 297 were
excluded due to clinical or sample exclusion criteria,
leaving 1,461 enrolled, of which 1,424 were from the
United States and 37 were from Canada (Figure 1) (12).
DEMOGRAPHICS, DIAGNOSIS, AND MEDICAL
HISTORY. As demonstrated in Table 1, 277 (19%) pa-
tients were diagnosed with acute HF and 1,184 (81%)
did not have acute HF after adjudication (site di-
agnoses for these 1,184 patients are displayed in Online
Table 1). This prevalence of 19% is signiﬁcantly less
than the 50% prevalence that was assumed at the
outset of the trial, which had a signiﬁcant effect on the
expected predictive values described earlier. Overall,
themean patient age was 56.4 15.7 years, 49.1%were
female, and 36.6% were black; 63.3% had hyperten-
sion, and 24.9% had a history of prior HF. The most
recent left ventricular ejection fraction (LVEF) mea-
surement before enrollment, available in 28% of the
patients (405 of 1,461), was mean 51  17%. Asthma,
chronic obstructive pulmonary disease, and a history
of lung cancer were present in 30.1%, 27.5%, and 2.8%
of the enrolled cohort, respectively; 58.5% of patients
reported being current or former smokers. Subjects
with acute HF were older and were more likely to have
diabetes, hypertension, prior HF, prior coronary artery
disease, chronic kidney disease, and atrial ﬁbrillation
compared with those without acute HF (all p < 0.001).
Not surprisingly, those with acute HF were more likely
to have lowermean LVEF at themost recent evaluation
before enrollment. Additionally,most patients (58.7%)
with acute HF had LVEF <50%.
Baseline characteristics of the subgroup of patients
with acute HF, comparing those with reduced versus
preserved ejection fraction, are presented in Online
Table 2.
NT-proBNP CONCENTRATIONS. The results of NT-
proBNP testing between those with and without
acute HF are shown in Figure 2. The median NT-
proBNP concentration of patients with acute HF
(2,844 pg/ml; interquartile range: 1,247 to 5,976 pg/ml)
was substantially higher than those without acute HF(98 pg/ml; interquartile range: 35 to 369 pg/ml;
p < 0.001 for difference).
The ROC curve for all patients (Central Illustration,
panel A) demonstrated an area under the curve (AUC)
of 0.91 (95% CI: 0.90 to 0.93; p < 0.001). The AUCs
derived from the age categories are depicted in the
Central Illustration, panel B. Among patients <50
(n ¼ 462), 50 to 75 (n ¼ 833), and >75 years of age
(n ¼ 166), NT-proBNP had AUCs of 0.97 (95% CI: 0.94
to 0.99), 0.89 (95% CI: 0.87 to 0.92), and 0.84 (95% CI:
0.78 to 0.90), respectively, for the diagnosis of acute
HF (all p < 0.001).
CUTPOINT ANALYSIS: IDENTIFICATION OF ACUTE
HF. The diagnostic sensitivities, speciﬁcities, PPV
and NPV, and likelihood ratios for age-stratiﬁed
diagnostic cutpoints in the study population are
depicted in Table 2. This cutpoint strategy was asso-
ciated with PPVs (primary endpoint) of 53.6% (95%
CI: 43.7% to 63.2%), 58.4% (95% CI: 53.7% to 63.0%),
and 62.0% (95% CI: 53.3% to 70.0%) for the age-
dependent cutoffs of 450, 900, and 1,800 pg/ml,
respectively. The corresponding sensitivities for each
cutoff were 85.7% (95% CI: 74.1% to 97.3%), 79.3%
(95% CI: 73.5% to 85.2%), and 75.9% (95% CI: 64.8% to
86.9%), respectively. Results using the FDA-approved
NT-proBNP cutpoints (125 and 450 pg/ml) are pre-
sented in Online Table 3. The 125- and 450-pg/ml
CENTRAL ILLUSTRATION NT-proBNP–Based Diagnosis of Acute HF: ROC Curves
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NPV 99.7% (95% CI 98.1%-100.0%)
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The receiver-operating characteristic curves for the NT-proBNP–based diagnosis of acute heart failure are presented for (A) all patients (n ¼ 1,461), and (B) across the
3 age groups: <50 years of age (n ¼ 462); 50 to 75 years of age (n ¼ 833); and >75 years of age (n ¼ 166). The sensitivity, speciﬁcity, PPV, NPV, and accuracy are
presented for the Youden index (A) for all patients, and (B) for each age group. AUC ¼ area under the curve; HF ¼ heart failure; NPV ¼ negative predictive value;
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; PPV ¼ positive predictive value; ROC ¼ receiver-operating characteristic.
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1196cutoffs were respectively associated with PPVs of
33.5% (95% CI: 31.7% to 35.3%) and 43.7% (95% CI:
40.5% to 46.8%); sensitivity of 96.7% (95% CI: 94.3%
to 99.1%) and 98.4% (95% CI: 95.3% to 100.0%).
Given a lower prevalence (19%) (Online Figure 1) of
acute HF than projected (which affects predictive
values), it is worthwhile to emphasize that the overall
LRþ for the age-stratiﬁed cutpoint strategy was as
predicted at 5.99 (95% CI: 5.05 to 6.93); LRþ values
for each cutoff were 14.08 (95% CI: 8.48 to 19.67),
4.95 (95% CI: 4.00 to 5.90), and 3.03 (95% CI: 1.94 to
4.13), respectively.
In multivariable logistic regression, an elevated
age-adjusted NT-proBNP had the highest OR of all
variables retained (OR: 11.80; 95% CI: 7.66 to 18.18;
p < 0.001). Other variables signiﬁcantly predictive of
acute HF included prior HF (OR: 2.67; 95% CI: 1.76 to
4.07; p < 0.001), interstitial edema on chest radiog-
raphy (OR: 4.70; 95% CI: 2.67 to 8.27; p < 0.001), rales
on lung examination (OR: 2.56; 95% CI: 1.35 to 4.87;p ¼ 0.004), and presence of peripheral edema on
physical examination (OR: 3.95; 95% CI: 2.56 to 6.09;
p < 0.001). The overall model C-statistic with these
variables was 0.933.
CUTPOINT ANALYSIS: EXCLUSION OF ACUTE HF.
The age-independent approach for ruling out acute
HF using the single cutpoint of 300 pg/ml exhibited
an NPV (primary endpoint) of 98.0% (95% CI: 96.9%
to 98.8%), and a speciﬁcity of 71.7% (95% CI: 69.1% to
74.3%). The LRwas 0.09 (95% CI: 0.05 to 0.13) in our
patient population (Table 2).
SUBGROUP FINDING. Subgroup analyses assessing
the AUC of the optimal NT-proBNP cutpoints for the
diagnosis or exclusion of acute HF are presented in
Table 3. AUCs were generally similar to previous de-
scriptions in men and women, or black versus
nonblack patients (15), with no signiﬁcant differences
between groups in AUC. Additionally, in certain
populations with conditions affecting the accuracy of
TABLE 2 NT-proBNP Cutpoints for the Diagnosis or Exclusion of Acute Decompensated HF
Acute HF þ Acute HF  Total
Conﬁrmatory (“rule-in”) cutpoints
<50 yrs
Test þ 30 26 56
Test  5 401 406
Total 35 427 462
50-75 yrs
Test þ 146 104 250
Test  38 545 583
Total 184 649 833
>75 yrs
Test þ 44 27 71
Test  14 81 95
Total 58 108 166
Rule-in, overall
Test þ 220 157 377
Test  57 1,027 1,084
Total 277 1,184 1,461
Exclusionary (“rule-out”) cutpoint
All patients
Test þ 260 335 595
Test  17 849 866
Total 277 1,184 1,461
Category Cutpoint, pg/ml Sensitivity Speciﬁcity PPV NPV LRþ LR
Conﬁrmatory (“rule-in”) cutpoints
<50 yrs (n ¼ 462) 450 85.7 (74.1–97.3) 93.9 (91.6–96.2) 53.6 (43.7–63.2) 98.8 (97.3–99.4) 14.08 (8.48–19.67) 0.15 (0.03–0.28)
50–75 yrs (n ¼ 833) 900 79.3 (73.5–85.2) 84.0 (81.2–86.8) 58.4 (53.7–63.0) 93.5 (91.5–95.0) 4.95 (4.00–5.90) 0.25 (0.18–0.32)
>75 yrs (n ¼ 166) 1,800 75.9 (64.8–86.9) 75.0 (66.8–83.2) 62.0 (53.3–70.0) 85.3 (78.4–90.2) 3.03 (1.94–4.13) 0.32 (0.17–0.47)
Rule-in, overall (n ¼ 1,461) 79.4 (74.7–84.2) 86.7 (84.8–88.7) 58.4 (54.5–62.1) 94.7 (93.5–95.8) 5.99 (5.05–6.93) 0.24 (0.18–0.29)
Exclusionary (“rule-out”) cutpoint
All patients (n ¼ 1,461) 300 93.9 (91.0–96.7) 71.7 (69.1–74.3) 43.7 (41.4–46.1) 98.0 (96.9–98.8) 3.32 (3.00–3.63) 0.09 (0.05–0.13)
The sensitivity, speciﬁcity, positive and negative predictive values, and positive and negative likelihood ratios are presented as % (95% conﬁdence interval) for the age-dependent rule-in cutoffs of 450, 900,
and 1,800 pg/ml for ages <50, 50–75, >75 years, and for the rule-out cutoff of 300 pg/ml, in all enrolled subjects.
HF ¼ heart failure; LRþ ¼ positive likelihood ratio; LR ¼ negative likelihood ratio; NPV ¼ negative predictive value; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; PPV ¼ positive predictive
value.
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comorbidities to those previously reported, with the
expected effect of reduced/preserved ejection frac-
tion, abnormal renal function (16), obesity (17), and
atrial ﬁbrillation (18). Similar results were seen in
subgroup analyses assessing the AUC of the FDA-
approved NT-proBNP cutpoints (125 and 450 pg/ml),
as demonstrated in Online Table 4.
DISCUSSION
Although widely used in U.S. clinical practice, the
age-stratiﬁed NT-proBNP rule-in cutpoint strategy for
diagnosis of acute HF and age-independent rule-out
cutpoint to exclude acute HF have not been pro-
spectively validated in a North American cohort. Our
results provide contemporary information about NT-
proBNP cutpoints to aid in the diagnosis and exclu-
sion of acute HF in a cohort of all-comer patients withacute dyspnea presenting to EDs. Our study repre-
sents a diverse range of patient groups, with
approximately 50% women and more than 40%
nonwhite patients. Results of the study indicate
excellent performance of NT-proBNP to identify or
exclude acute HF, and support the utility of the
widely-used age-stratiﬁed diagnostic approach for its
use, while also verifying high NPV of 300 pg/ml to
exclude acute HF.
Notably, the overall age of the patients diagnosed
with acute HF was relatively young in comparison to
other cohorts (2). The characteristics of participants
in this study are consistent with data suggesting that
the demographics of ED patients with acute HF, as
well as those of patients with measurable NT-proBNP,
have changed compared with the last major evalua-
tion 12 years ago (6,7). It is also noteworthy that the
prevalence of acute HF in this study of all-comers
with acute dyspnea (n ¼ 277; 19%) was considerably
TABLE 4 Compariso
for BNP or NT-proBN
Large Trials of Acute
First Author/Study,
Year (Ref. #)
Maisel et al., 2002 (4)
Januzzi et al., 2005 (2
Maisel et al., 2010 (27
ICON-RELOADED
BNP ¼ B-type natriuretic p
as in Tables 2 and 3.
TABLE 3 Comparison of ROC Curves for NT-proBNP–Based Diagnosis of Acute HF Across Patient Subgroups
Sensitivity Speciﬁcity PPV NPV AUC
p Value for
Difference in AUC
Patients with eGFR <60.0 ml/min/1.73 m2 89.3 (84.0–94.6) 68.3 (61.6–75.0) 66.5 (61.4–71.2) 97.3 (90.1–99.3) 0.872 0.12
Patients with eGFR $60.0 ml/min/1.73 m2 70.3 (62.7–77.9) 89.6 (87.6–91.7) 51.9 (46.3–57.4) 98.1 (96.8–98.8) 0.907
Patients with body mass index <30.0 kg/m2 90.3 (84.8–95.7) 85.0 (81.9–88.0) 56.4 (51.1–61.5) 100.0 (—) 0.946 0.001
Patients with body mass index $30.0 kg/m2 72.1 (65.0–79.2) 87.0 (84.2–89.8) 60.7 (54.9–66.1) 96.2 (94.1–97.6) 0.896
Male 80.5 (74.5–86.4) 84.8 (81.9–87.8) 61.0 (56.0–65.8) 97.5 (95.5–98.6) 0.908 0.44
Female 77.8 (69.9–85.6) 88.5 (86.0–91.1) 54.5 (48.5–60.5) 98.5 (97.0–99.3) 0.922
Black 82.4 (73.8–91.1) 90.4 (87.7–93.2) 58.7 (51.2–65.8) 98.7 (97.0–99.4) 0.933 0.16
Nonblack 78.7 (73.0–84.4) 84.5 (81.9–87.2) 58.5 (53.9–62.9) 97.9 (96.2–98.8) 0.908
Presence of atrial ﬁbrillation 87.2 (80.5–94.0) 56.6 (47.8–65.4) 60.7 (55.5–65.8) 100.0 (—) 0.807 <0.001
Absence of atrial ﬁbrillation 75.6 (69.3–81.8) 90.4 (88.6–92.1) 57.1 (52.1–62.0) 98.0 (96.8–98.7) 0.918
Patients with HFrEF 90.8 (85.1–96.5) 38.6 (24.2–53.0) 76.7 (72.1–80.8) 75.0 (38.7–93.5) 0.646 0.11
Patients with HFpEF 72.6 (61.5–83.7) 68.6 (58.8–78.4) 62.5 (54.1–70.2) 80.4 (68.2–88.7) 0.758
Values are % (95% conﬁdence interval). Performed with the Elecsys proBNP II Assay in all enrolled subjects. Sensitivity, speciﬁcity, and PPV refer to results for age-adjusted triple cutoff, whereas NPV refers
to results for the age-independent rule-out cutoff of 300 pg/ml.
AUC ¼ area under the curve; eGFR ¼ estimated glomerular ﬁltration rate; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction; ROC ¼ receiver-
operating characteristic; other abbreviations as in Table 2.
Januzzi, Jr. et al. J A C C V O L . 7 1 , N O . 1 1 , 2 0 1 8
NT-proBNP in the Emergency Department M A R C H 2 0 , 2 0 1 8 : 1 1 9 1 – 2 0 0
1198lower than projected (vs. 50%); in comparison, a
recent report from Singapore and New Zealand con-
ﬁrms reduced prevalence of HF in dyspneic patients
(36% and 24%, respectively) (19). This may suggest
use of the ED by patients with acute HF may be
declining, despite a rise in overall prevalence of the
diagnosis. These trends may be caused by the
increasing use of programs aimed at reducing ED HF
visits, HF hospitalization, and HF rehospitalization
(20). Despite differences in demographics compared
with older studies and lower prevalence, NT-proBNP
had excellent sensitivity, speciﬁcity, and area under
the ROC for diagnosis of acute HF, and the age-
adjusted cutoff had an OR >10 for the diagnosis of
HF, substantially stronger than traditional variables
from history, physical examination, or other forms of
laboratory testing. Importantly, we noted lower than
expected PPV, which is explainable by the lower
prevalence of acute HF in this population; given the
lower-than-expected prevalence of acute HF (whichns of Area Under the ROC Curve Along With LRþ and LR
P Assays to Diagnose or Exclude Acute HF in Various
Dyspnea
Biomarker N AUC
Overall LRþ for
“Rule In”
Overall LR for
“Rule Out”
BNP 1,586 0.91 2.60 0.05
) NT-proBNP 600 0.94 4.27 0.11
) NT-proBNP 1,641 0.91 2.51 0.07
NT-proBNP 1,461 0.91 5.99 0.09
eptide; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; other abbreviationsaffects the stability of the statistical predictive value),
using LRþ and LR may be a better approach for
assessing the performance of the test than PPV and
NPV.
Taken in context, the performance of NT-proBNP
in ICON-RELOADED compares favorably with other
large, pivotal trials of BNP and NT-proBNP testing
(Table 4). In this regard, compared with the ﬁrst ICON
study, we found slightly higher overall LRþ (5.99 vs.
4.27) and slightly lower overall LR (0.09 vs. 0.11). In
the balance, the LR results in the present study
conﬁrm that elevated age-stratiﬁed cutoff results may
be used as an aid in the diagnosis of acute HF,
whereas an NT-proBNP concentration <300 pg/ml
provides a substantial ability to exclude the presence
of acute HF. Despite not being on the package insert,
the age-stratiﬁed approach has been incorporated in
clinical practice guidelines (5) and textbooks, and is
used globally at present. The FDA-approved cutoffs
are for outpatient application, in particular, for
excluding the presence of chronic HF on the basis of
their high NPV. In contrast, among a more acutely
dyspneic population, where natriuretic peptide as-
says are more widely used, these cutoffs deliver
reasonable NPV, but their PPV is undermined by the
lack of speciﬁcity. Clinicians should consider the
venue in which they are using NT-proBNP, and select
cutoffs accordingly. Having consistency in FDA-
approved cutoffs, as well as clinical practice guide-
lines, would ease the confusion surrounding the
different cutoffs.
Analysis of pre-speciﬁed subgroups with
demographics or comorbidities that could potentially
PERSPECTIVES
COMPETENCY IN PATIENT CARE: For patients presenting to
the ED with acute dyspnea categorized by age <50, 50 to 75,
and $75 years, accurate diagnosis of HF may be based on ICON
NT-proBNP cutoff levels of 450, 900, and 1,800 pg/ml,
respectively, and acute HF is largely excluded when the level is
below 300 pg/ml.
TRANSLATIONAL OUTLOOK: Future studies should assess
the generalizability of these thresholds in patients evaluated in
other care settings and with manifestations of HF other than
dyspnea.
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strated that the diagnostic and exclusionary perfor-
mance of the test remained accurate in these patient
subgroups, with consistent effects of sex and race
(15), abnormal renal function (16), obesity (17), and
atrial ﬁbrillation (18) on sensitivity or speciﬁcity of
NT-proBNP.
Early and accurate diagnosis of patients with acute
dyspnea in the ED is essential, as delayed treatment
for acute HF is associated with increased mortality
(21). Studies from PRIDE (22,23), the Canadian-based
IMPROVE-CHF (Improved Management of Patients
with Congestive Heart Failure) study (24), the
ADHERE (Acute Decompensated Heart Failure Na-
tional Registry) analysis (25), and others (21) suggest
that prompt, accurate diagnosis reduces indecision,
potentially improves outcomes, and leads to a
reduction in health care expenditures. Validation of
the ICON diagnostic cutoffs in an all-comers,
contemporary cohort may thus aid in enhancing
diagnosis of acute HF in the ED.
STUDY LIMITATIONS. The clearest limitation of the
study is that fewer than expected patients with acute
HF were enrolled, which is reﬂected in the lower PPV
result, as PPV is largely dependent on the prevalence
of the disease. For example, the same assay tested
here would have a PPV of 80% to 90% if the preva-
lence of acute HF was 50%. As a matter of fact, the
PPV noted in this study was exactly as projected
based on the lower prevalence of acute HF (Online
Figure 1). In this regard, the use of LRþ to express
the performance of a test is arguably a more reliable
approach when comparing tests from 2 different
studies with different disease prevalence, and the
results conﬁrm the expected performance of the age-
adjusted cutoff approach studied in this analysis.
Similarly, in the BNP (Breathing Not Properly) multi-
national study (4), which had a higher prevalence of
patients with HF (47%), the PPV was indeed higher
(71% to 83%, depending upon the BNP level), but the
LRþwas lower (3.4) when evaluating BNP $100 pg/ml
(26). As with BNP, certain clinical factors, such as
impaired renal function, can increase NT-proBNP
levels in the absence of HF and deliver a lower
speciﬁcity as well as PPV. However, age stratiﬁcation
largely addresses the effects of renal function (16). As
seen in the AUC curve, using a higher NT-proBNP
cutpoint would result in better speciﬁcity and better
PPV, as was the case of BNP in the Breathing Not
Properly Study (4). Lower prevalence of acute HF in
this study likely reﬂects the evolution in practices
surrounding ED use for HF over the last decade, infavor of urgent care and ofﬁce-based practice. It is
important to note that despite the lower prevalence
of acute HF in the study cohort, the performance of
the cutoffs for exclusion of acute HF was great.
Lastly, because this study was conducted in the
United States and Canada, the generalizability of the
ﬁndings outside of this geographic region may be
limited.
CONCLUSIONS
The ICON-RELOADED study demonstrates that the
NT-proBNP cutoffs proposed in the ﬁrst ICON study
perform consistently in a current, multicenter cohort
of all-comer patients. As in all prior studies of BNP or
NT-proBNP, our results conﬁrm that elevated NT-
proBNP may aid in identiﬁcation of acute HF,
whereas an NT-proBNP <300 pg/ml provides a strong
ability to exclude acute HF. Despite changes in
prevalence, demographics, comorbidities, and man-
agement of patients with HF nearly 15 years after NT-
proBNP was ﬁrst developed as a biomarker test, the
utility of the assay for both the diagnosis and exclu-
sion of acute HF in the ED setting endures.
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